tandutinib

Small moleculeexperimental

Chemistry & pharmacology

Loading structure…

SMILES

COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Mol. weight
562.72 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 4-(6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl)piperazine-1-carboxylic acid (4-isopropoxyphenyl)amide
  • ct53518
  • ct53518
  • ct53518
  • ct 53518
  • ct-53518
  • ct-53518
  • ct-53518
  • mln-0518
  • mln-0518
  • mln518
  • mln518
  • mln518
  • mln 518
  • mln-518
  • mln-518
  • mln-518
  • tandutinib
  • tandutinib
  • tandutinib
  • tandutinib
  • tandutinib

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00904852Phase 1Jun 1, 2009Millennium Pharmaceuticals
NCT00667394Phase 2Apr 1, 2008National Cancer Institute (NCI), National Institutes of Health (NIH)
NCT00379080Phase 1/Phase 2 (Phase 2)Jan 1, 2007National Cancer Institute (NCI)
NCT00408902Phase 2Nov 1, 2006Case Western Reserve University, National Cancer Institute (NCI)
NCT00390468Phase 2Oct 1, 2006National Cancer Institute (NCI), University of Texas at Houston
NCT00297921Phase 1/Phase 2 (Phase 2)Feb 27, 2006Millennium Pharmaceuticals
NCT00274248Phase 1Mar 1, 2005Millennium Pharmaceuticals
NCT00064584Phase 1May 1, 2002Millennium Pharmaceuticals
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Millennium PharmaceuticalsFor profit4422002
National Cancer Institute (NCI)Government4412006
Case Western Reserve UniversityAcademic/Hospital1012006
National Institutes of Health (NIH)Government1012008
University of Texas at HoustonAcademic/Hospital1012006
5 organizations
Page 1 / 1